Literature DB >> 7510940

Development and prevention of metastasis.

E C Kohn1.   

Abstract

Metastatic spread of malignancy is the primary cause of treatment failure and subsequent death in cancer patients. All cancers have the capability to metastasize, however, there are notable exceptions which rarely if ever metastasize. These include basal cell carcinoma, or cancers which are primarily locally invasive such as primary brain cancers. Is metastasis is an earlier process in cancer progression than originally hypothesized? Over 70% of patients have occult or overt metastatic disease at the time of presentation. Thus, the overwhelming proportion of patients have disease which is not surgically resectable for cure at the time of diagnosis. Metastasis is a continuous process commencing early in the growth of the primary tumor before it is clinically detectable by the most sensitive of means. In addition, metastases have the propensity to metastasize. The size and age variation in metastases, their dispersed anatomic locations, the local vascular and lymphatic environment, and their heterogeneous composition hinder complete surgical extirpation of disease and limit the effective concentration of anticancer drugs that can be delivered to metastatic colonies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7510940

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Kinetics of marked development of lung metastasis of rat prostatic carcinomas transplanted in syngeneic rats.

Authors:  Laiyuan Zhao; Mitsuru Futakuchi; Shugo Suzuki; Yoshiaki Ohhara; Takashi Hashimoto; Tatsuya Suzuki; Tadao Manabe; Tomoyuki Shirai
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma.

Authors:  Ying-Fu Liu; Peng-Fei Zhang; Mao-Yu Li; Quo-Qing Li; Zhu-Chu Chen
Journal:  Clin Exp Metastasis       Date:  2011-03-02       Impact factor: 5.150

4.  Modification of an in vivo lung metastasis model of hepatocellular carcinoma by low dose N-nitrosomorpholine and diethylnitrosamine.

Authors:  Hiroko Yoshino; Mitsuru Futakuchi; Young-Man Cho; Kumiko Ogawa; Fumitaka Takeshita; Norio Imai; Seiko Tamano; Tomoyuki Shirai
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 5.  Galectin-3 and metastasis.

Authors:  Yukinori Takenaka; Tomoharu Fukumori; Avraham Raz
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

6.  Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources.

Authors:  U V Sathisha; Smitha Jayaram; M A Harish Nayaka; Shylaja M Dharmesh
Journal:  Glycoconj J       Date:  2007-05-25       Impact factor: 2.916

Review 7.  Polyphenolic Nutrients in Cancer Chemoprevention and Metastasis: Role of the Epithelial-to-Mesenchymal (EMT) Pathway.

Authors:  Haneen Amawi; Charles R Ashby; Temesgen Samuel; Ramalingam Peraman; Amit K Tiwari
Journal:  Nutrients       Date:  2017-08-21       Impact factor: 5.717

8.  Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma.

Authors:  Mitsuru Futakuchi; Kumiko Ogawa; Masashi Sano; Seiko Tamano; Fumitaka Takeshita; Tomoyuki Shirai
Journal:  Jpn J Cancer Res       Date:  2002-10

9.  Proteomic analysis of tumor tissue in CT-26 implanted BALB/C mouse after treatment with ascorbic acid.

Authors:  Jihye Lee; Gunsup Lee; Jin Hee Park; Sukchan Lee; Chang-Hwan Yeom; Byungjo Na; Seyeon Park
Journal:  Cell Mol Biol Lett       Date:  2011-12-02       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.